ACCESSWIRE

The newsfeed available here is provided by our content partner ACCESSWIRE. This is one of the most important and widest-reaching press services, providing news, press releases and multimedia content to the media, journalists and the public.

The NewsWire Hub ("X-Billboard") currently comprises five of the most important international news sources and is supplemented by a stock market information service. The individual newswire services complement each other and form a complementary information offering that covers more than three quarters of the official news sources on which editorial offices worldwide base their stock market reporting. Your advantage: You will find everything here in one overview. You can navigate to the individual sections using the control elements. In the terminal view, you can carry out individual searches at company level.
System-State: Number of processed items 3.537 Notifications successully processed since Inception

ACCESSWIRE is an important news source for private investors, investors and traders that can be accessed via the X-Billboard. It is part of the Newswire Hub, which bundles important international news sources for stock market players in one central location. If you want to get a quick overview, you can easily scroll through the headlines. Those who want to take a closer look at the news can use the detailed views of the info cards to directly access the respective news item and other analysis tools.

NEWS
EXPLORER
GB0034330679
State: 23.11.2024 | 6AM
Do you already know our new terminal view? Click here.
FIGI: BBG000QY3TF3
AGL

ANGLE PLC LS-,10
GICS: - · Sector: Health Care · Sub-Sector: Health Care
NAME
ANGLE PLC LS-,10
ISIN
GB0034330679
TICKER
AGL
MIC
AIMX
REUTERS
AGL.L
BLOOMBERG
AGL LN
Fri, 15.11.2024       ANGLE

RESULTS FROM WORK TO DEVELOP A PARSORTIX-BASED Her2 assay KIT SHOWCASED AT INTERNATIONAL LIQUID BIOPSY CONFERENCEParsortix-based HER2 kit being developed to provide an optimised, easily implemented, solution to enable product customers to undertake longitudinal, repeat assessment of HER2 status in breast cancerGUILDFORD, SURREY / ACCESSWIRE / Novem...
Fri, 15.11.2024       ANGLE

CTC PD-L1 assay enables longitudinal monitoring of PD-L1 status in lung cancer patients and may help to advance personalised treatment GUILDFORD, UNITED KINGDOM / ACCESSWIRE / November 15, 2024 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug d...
Wed, 13.11.2024       ANGLE

PARSORTIX-BASED ASSAYS SHOWCASED AT THE EUROPEAN ASSOCIATION FOR CANCER RESEARCH LIQUID BIOPSIES CONFERENCETwo posters highlight the importance of epitope-independent CTC enrichment and molecular characterisation of CTCs GUILDFORD, SURREY / ACCESSWIRE / November 13, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with...
Mon, 11.11.2024       ANGLE

ANGLE plc ("the Company")DNA ANALYSIS OF PARSORTIX-ENRICHED CTCS AND CTDNA PROVIDES COMPLEMENTARY INFORMATION IN NSCLC PATIENTS TREATED WITH ASTRAZENECA'S OSIMERTINIBThe addition of CTC-DNA analysis to clinical trials could identify patients developing treatment resistance prior to disease progressionCTC analysis identifies druggable targ...
Thu, 17.10.2024       ANGLE

PUBLICATION DEMONSTRATES POTENTIAL FOR multi-marker CTC profiling IN EARLY PROSTATE CANCERParsortix enriched CTCs detected at high rates in localised diseaseMulti-marker profiling of CTCs could support development of targeted therapies and help stratify patients in clinical trials GUILDFORD, SURREY / ACCESSWIRE / October 17, 2024 / ANGLE plc (AIM:A...
Thu, 26.09.2024       ANGLE

GUILDFORD, SURREY / ACCESSWIRE / September 26, 2024 / Whole Genomic Sequencing and machine learning identifies key cancer genes associated with DNA proliferation and repairANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical...
Thu, 26.09.2024       ANGLE

Interim Results for the six months ended 30 June 2024LARGE PHARMA STRATEGY IMPLEMENTED SUCCESSFULLYThree Large Pharma contracts secured each with substantial revenue potentialStrategic decision post period end to focus resources on pharma services GUILDFORD, SURREY / ACCESSWIRE / September 26, 2024 / ANGLE plc ("ANGLE" or "the Compan...
Mon, 23.09.2024       ANGLE

ANGLE ANNOUNCES NEXT GENERATION SEQUENCING ASSAY AGREEMENT WITH NUPROBEOption for exclusive licence to highly sensitive NGS assay for use with CTCs and dual analysis of CTCs with ctDNACombining the Parsortix system with comprehensive DNA molecular analysis opens up a broad range of pharma services opportunities GUILDFORD, SURREY / ACCESSWIRE / Sept...
Thu, 19.09.2024       ANGLE

New pharma agreement for Parsortix CTC analysisGUILDFORD, SURREY / ACCESSWIRE / September 19, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce that it has signed an agreement with ...
Tue, 17.09.2024       ANGLE

Notice of Interim Results and Webcast GUILDFORD, SURREY / ACCESSWIRE / September 17, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, will be releasing its interim results for the six months ended 30 Jun...

The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.

RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.

Note: The newswire crosslink panel in the upper area allows you to quickly and conveniently access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted research.


On behalf of the international investor community, we would like to thank AccessWire for providing the news and data feeds